Name: | Omeprazole |
---|---|
PubChem Compound ID: | 130564 |
Description: | A highly effective inhibitor of gastric acid secretion used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits the H(+)-K(+)-ATPase (H(+)-K(+)-EXCHANGING ATPASE) in the proton pump of GASTRIC PARIETAL CELLS. |
Molecular formula: | C34H36MgN6O6S2 |
Molecular weight: | 713.123 g/mol |
Synonyms: |
(-)-Omeprazole magnesium; Nexium; Prilosec OTC; Esomeprazole magnesium [USAN:INN]; 320416-93-1; 95382-33-5; 202742-32-3; 161973-10-0; H 199/18; D05259.
show more » |
Name: | Omeprazole |
---|---|
Name (isomeric): | DB00338 |
Drug Type: | small molecule |
Description: | A highly effective inhibitor of gastric acid secretion used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits the H(+)-K(+)-ATPase (H(+)-K(+)-EXCHANGING ATPASE) in the proton pump of GASTRIC PARIETAL CELLS. |
Synonyms: |
OMP; Omeprazol [INN-Spanish]; Omeprazolum [INN-Latin]; OMEP; OMZ; Omeprazole magnesium
|
Brand: | Gasec, Pepticum, Ulcozol, Gastrimut, Danlox, Omid, Omesek, Exter, Aulcer, Inhibitron, Omed, Omeprol, Zefxon, Ocid, Audazol, Miracid, Zegerid, Belmazol, Emeproton, Ulsen, Pepticus, Antra, Prazidec, Mepral, Omebeta 20, Omezolan, Demeprazol, Olexin, Ramezol, Morecon, Regulacid, Prazolit, Result, Erbolin, Nilsec, Ulcometion, Paprazol, Dizprazol, Omisec, Gastroloc, Lomac, Logastric, Omeprazon, Ozoken, Prazentol, Losec, Ultop, Secrepina, Procelac, Ulcsep, Ceprandal, Prysma, Parizac, Miol, Indurgan, Elgam, Omapren, Omegast, Lensor, Inhipump, Victrix, Ulzol, Zepral, Gibancer, Zoltum, Sanamidol, Osiren, Mopral, Omizac, Peptilcer, Desec, Ompanyt, Proclor, Prilosec, Zimor, Ulcesep, Nopramin, Tedec Ulceral, Epirazole, Ortanol, Omezol, Omepral, Dudencer, Ulceral |
Category: | Anti-Ulcer Agents, Enzyme Inhibitors, Proton-pump Inhibitors |
CAS number: | 73590-58-6 |
Indication: | For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use. |
---|---|
Pharmacology: |
Omeprazole is a compound that inhibits gastric acid secretion and is indicated in the treatment of gastroesophageal reflux disease (GERD), the healing of erosive esophagitis, and H. pylori eradication to reduce the risk of duodenal ulcer recurrence. Omeprazole belongs to a new class of antisecretory compounds, the substituted benzimidazoles,...
show more » |
Mechanism of Action: | Omeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+-ATPase in the gastric parietal cell. By acting specifically on the proton pump, omeprazole blocks the final step in acid production, thus reducing gastric acidity. |
Absorption: | Absorption is rapid, absolute bioavailability (compared to intravenous administration) is about 30-40% at doses of 20-40 mg. |
Protein binding: | 95% |
Biotransformation: | Hepatic. |
Route of elimination: | Urinary excretion is a primary route of excretion of omeprazole metabolites. |
Half Life: | 0.5-1 hour |
Clearance: | total body cl=500-600 mL/min [healthy] 250 mL/min [Geriatric] 70 mL/min [Hepatic Impairment] 10 - 62 mL/min/1.73 m2 [Renal Impairment] |
Toxicity: | Symptoms of overdose include confusion, drowsiness, blurred vision, tachycardia, nausea, diaphoresis, flushing, headache, and dry mouth. |
Affected organisms: | Humans and other mammals |
Food interaction: |
| ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Drug interaction: |
|